Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of budesonide on the EML and EMLc: - update the listing description of inhalation delivery systems for consistency across the Model Lists and to better reflect product characteristics; - to remove flunisolide as a therapeutic alternative to budesonide from the EML and EMLc due to low market availability.